ИСПОЛЬЗОВАННАЯ ЛИТЕРАТУРА

1. Gerritsen J., et al. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr (2011) 6:209-240.
2. Distrutti E, et al. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol 2016;21;22(7): 2219-41.
3. Bull MJ, Plummer NT. Part 1: The Human Gut Microbiome in Health and Disease. Integr Med (Encinitas) 2014;13(6):17-22.
4. McCarville JL, et al. Novel perspectives on therapeutic modulation of the gut microbiota. Therap Adv Gastroenterol 2016;9(4): 580-93.
5. IBS in American survey – oct 2015 conducted by the American Gastroenterological Association.
6. Enck P., et al. Irritable Bowel Syndrome. Nat Rev Dis Primers 2016 2 :16014.
7. Canavan C, et al. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 2014;40:1023-34.
8. Foxx-Orenstein AE. New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol 2016;9(3):354-75.
9. Общие рекомендации Всемирной гастроэнтерологической организации. Синдром раздраженного кишечника. 2015.
10. Lacy B.E., et al. Bowel Disorders. Gastroenterology 2016;150:1393-1407.
11. Ducrotté P. Microbiota and functional gastrointestinal disorders. In Marteau P., Doré J (coord). Gut Microbiota, A full-fledged organ. Paris : John LibbeyEurotext, 2017, chapter 12, p.113-24.
12. Hod K, Ringel Y. Probiotics in functional bowel disorders. Best Pract Res Clin Gastroenterol 2016;30(1):89-97.
13. Farzaei MH, et al. The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. J Neurogastroenterol Motil 2016;22(4):558-74.
14. Mertz H., et al. Altered Rectal Perception is a Biological Marker of Patients With Irritable Bowel Syndrome. Gastroenterology 1995;109:40-52.
15. Ohman L., et al. Pathogenesis of IBS : role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 7,163-173 (2010).
16. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behavior. Nat Rev Neurosci 2012;13(10):701-12.
17. Bharucha AE, et al. Common Functional Gastroenterological Disorders Associated With Abdominal Pain. Mayo Clin Proc 2016;91(8):1118-32.
18. https://patient.info/health/irritable-bowel-syndrome-diet-sheet, дата обращения: 2017/05/12.
19. Johannesson E, Ringström G, Abrahamsson H, et al. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol 2015;21(2):600-8.
20. Tack J., et al. Modern Management of Irritable Bowel Syndrome : More than Motility. Dig Dis 2016;34:566-573.
21. Bull MJ, Plummer NT. Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis. Integr Med (Encinitas) 2015;14(1): 25-33.
22. Общие рекомендации Всемирной гастроэнтерологической организации. Пробиотики и пребиотики. 2017.
23. O'Mahony L, et al. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol Gastrointest Liver Physiol 2006;290(4):G839-45.
24. O'Hara AM, et al. Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology 2006;118(2):202-15.
25. Konieczna P, et al. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 2012;61:354-66.
26. O'Mahony L, et al. Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles. Gastroenterology 2005;128:541-51.
27. Whorwell PJ, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Am J Gastroenterol 2006;101(7):1581-90.